Abstract
Lung cancer is still the leading cause of cancer related death worldwide. Fibroblast growth factor receptor (FGFR) is a tirosine-kinase receptor that is seen to be amplified or mutated in non-small cell lung cancer (NSCLC) and it plays a crucial role in tumour development and maintenance.
The authors analyzed the state of the art of FGFR by reviewing the current literature. Fibroblast growth factor (FGF)-FGFR pathway and their aberrations are described, with the evaluation of their possible prognostic role in NSCLC and in particular in squamous cell carcinomas, in which FGFR is more often amplified. New therapeutic agents targeting FGFR signaling have been developed and are now in clinical evaluation.
Dysregulation of FGF signaling in tumour cells is related to FGFR gene amplification or mutation, although it is still uncertain which of these aberrations represents a real predictor of response to specific inhibitors. However, recent evidence has questioned whether FGFR is a real target in squamous cell histology. The effectiveness of FGFR inhibitors is also still unclear since there are no clinical data on selected patients. Moreover, the management of specific side effects related to inhibition of the physiological role of FGF should be more thorough.
Keywords: fifbroblast growth factor receptor (FGFR), non-small-cell lung cancer (NSCLC), amplification, tumorigenic role, prognostic role, targeted inhibitors.
Anti-Cancer Agents in Medicinal Chemistry
Title:Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy
Volume: 16 Issue: 9
Author(s): Federica Biello, Giovanni Burrafato, Erika Rijavec, Carlo Genova, Giulia Barletta, Anna Truini, Simona Coco, Maria Giovanna Dal Bello, Angela Alama, Francesco Boccardo and Francesco Grossi
Affiliation:
Keywords: fifbroblast growth factor receptor (FGFR), non-small-cell lung cancer (NSCLC), amplification, tumorigenic role, prognostic role, targeted inhibitors.
Abstract: Lung cancer is still the leading cause of cancer related death worldwide. Fibroblast growth factor receptor (FGFR) is a tirosine-kinase receptor that is seen to be amplified or mutated in non-small cell lung cancer (NSCLC) and it plays a crucial role in tumour development and maintenance.
The authors analyzed the state of the art of FGFR by reviewing the current literature. Fibroblast growth factor (FGF)-FGFR pathway and their aberrations are described, with the evaluation of their possible prognostic role in NSCLC and in particular in squamous cell carcinomas, in which FGFR is more often amplified. New therapeutic agents targeting FGFR signaling have been developed and are now in clinical evaluation.
Dysregulation of FGF signaling in tumour cells is related to FGFR gene amplification or mutation, although it is still uncertain which of these aberrations represents a real predictor of response to specific inhibitors. However, recent evidence has questioned whether FGFR is a real target in squamous cell histology. The effectiveness of FGFR inhibitors is also still unclear since there are no clinical data on selected patients. Moreover, the management of specific side effects related to inhibition of the physiological role of FGF should be more thorough.
Export Options
About this article
Cite this article as:
Biello Federica, Burrafato Giovanni, Rijavec Erika, Genova Carlo, Barletta Giulia, Truini Anna, Coco Simona, Bello Giovanna Dal Maria, Alama Angela, Boccardo Francesco and Grossi Francesco, Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (9) . https://dx.doi.org/10.2174/1871520616666160204112347
DOI https://dx.doi.org/10.2174/1871520616666160204112347 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Interaction of Tumor Suppressor p53 with DNA and Proteins
Current Pharmaceutical Biotechnology Mechanisms of Angiogenesis: Perspectives from Antiangiogenic Tumor Therapies
Current Angiogenesis (Discontinued) Design of Fucoidan Functionalized - Iron Oxide Nanoparticles for Biomedical Applications
Current Drug Delivery Exosomes Harnessed as Nanocarriers for Cancer Therapy - Current Status and Potential for Future Clinical Applications
Current Molecular Medicine Preclinical Development of Novel Anti-Glioma Drugs Targeting the Endoplasmic Reticulum Stress Response
Current Pharmaceutical Design Marine Metabolites Overcoming or Circumventing Multidrug Resistance Mediated by ATP-Dependent Transporters: A New Hope for Patient with Tumors Resistant to Conventional Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Antiangiogenic Therapy and Ovarian Cancer
Current Women`s Health Reviews Oncogenomic Approaches in Exploring Gain of Function of Mutant p53
Current Genomics Patent Selections
Recent Patents on Biomarkers Drugs Acting on the Beta Isoform of Human Topoisomerase II (p180)
Current Medicinal Chemistry - Anti-Cancer Agents Kinase Inhibitor Conjugates
Current Pharmaceutical Design Gallium-68 in Medical Imaging
Current Radiopharmaceuticals In Vitro and In Vivo Models for Analysis of Resistance to Anticancer Molecular Therapies
Current Medicinal Chemistry Non-Viral Delivery of RNA Interference Targeting Cancer Cells in Cancer Gene Therapy
Current Gene Therapy Peripheral Benzodiazepine Receptor Ligands and their Anti-Inflammatory Effects
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery A Comprehensive Review on Exosomes and Microvesicles as Epigenetic Factors
Current Stem Cell Research & Therapy Pathophysiology and Pharmacological Targeting of Tumor-Induced Bone Disease: Current Status and Emerging Therapeutic Interventions
Current Medicinal Chemistry Recent Development of Copolymeric Nano-Drug Delivery System for Paclitaxel
Anti-Cancer Agents in Medicinal Chemistry Radioiodinated Ginger Compounds (6-gingerol and 6-shogaol) and Incorporation Assays on Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry